According to DRG epidemiology, more than 30 million people in the United States experience migraines, and more than 10% of migraineurs have chronic migraine (CM). Migraine prophylaxis is a core…
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin; it typically develops in early childhood and can persist into…
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin, which typically develops in early childhood and can persist into…
MARKET OUTLOOK Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality,…
MARKET OUTLOOK Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds…
For the 3.8 million people in the United States with Alzheimer’s disease (AD) dementia, approved pharmacotherapy is limited to only modestly effective procognitive symptomatic agents (e.g.,…
MARKET OUTLOOK Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. Historically, treatment of pediatric CD would begin with safe, albeit often…
NASH has the potential to be a large and lucrative therapy market owing to the disease’s prevalence and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
MARKET OUTLOOK Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal…
The drug landscape for major depressive disorder (MDD) consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Agents for treating MDD span…
According to DRG epidemiology, over 30 million people in the EU5 suffer migraines and over 10% of migraineurs suffer chronic migraine. Migraine prophylaxis is a core treatment approach for high-…
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
The asthma market in the EU5 is highly competitive. Many approved agents are available, including maintenance therapies—LABA/ICS FDCs (e.g., GSK’s Seretide and Relvar, AstraZeneca’s Symbicort…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees of vasculopathy that manifest as Raynaud…